RxDoctor Payments Data

Lica Monobe, PA

Physician Assistant · Mt Sterling, KYNPI 1679152904

Payments from drug & device makers

$6,667in general payments, 2019–2025

Across 318 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1K
  • Otsuka America Pharmaceutical, Inc.$701
  • AbbVie$588
  • AstraZeneca$489
  • Calliditas Therapeutics US Inc.$426
  • Boehringer Ingelheim$351
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,56398%
  • Education$1032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,667 in reported general payments places this provider in the 95th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$771
Medicare patients
14
Services billed
15

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$107,314
JardianceEmpagliflozin62$64,971
EliquisApixaban63$53,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$37,501
FarxigaDapagliflozin Propanediol45$35,276
JanuviaSitagliptin Phosphate27$27,182
VraylarCariprazine Hcl18$26,311
Breo ElliptaFluticasone/Vilanterol46$23,658
Tresiba Flextouch U-100Insulin Degludec17$13,535
Tresiba Flextouch U-200Insulin Degludec13$12,563
TradjentaLinagliptin16$12,362
XareltoRivaroxaban15$8,912
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$8,732
SymbicortBudesonide/Formoterol Fumarate28$7,644
Albuterol Sulfate HfaAlbuterol Sulfate201$7,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$115$107,314101 claims
Boehringer IngelheimJardiance, Tradjenta$351$77,33378 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$304$67,137110 claims
PfizerEliquis$180$53,67163 claims
AstraZenecaFarxiga, Symbicort$489$42,92073 claims
AbbVieVraylar, Linzess$588$32,98430 claims
MerckJanuvia$50$27,18227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Mt Sterling

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →